Posted: April 23, 2009

Genetic Immunity to Attend CLINAM European Conference for Clinical Nanomedicine

(Nanowerk News) Genetic Immunity has announced that Julianna Lisziewicz, Chief Executive Officer of the Company will be presenting at the European Conference for Clinical Nanomedicine, to be held from April 26-29, 2009 at the Basel Convention Center in Basel, Switzerland.
"The participants of this conference are working on nanotechnology-based drugs and biologics which have novel forms of therapeutic functionality meant to improve their efficacy and limit their negative side-effects. The interest in this clinical nanomedicine conference suggests that European entrepreneurs can be competitive globally and perhaps even spearhead the development of Nanomedicines. With our lead Nanomedicine Vaccine, the DermaVir Patch which is already in Phase II clinical trials, we are pioneering the field of Nanovaccines. Nanovaccines are just emerging as potential treatment and prevention solutions, and have recently gained recognition in the treatment of HIV, cancer and hepatitis. I look forward to exchange scientific and business information with other participants at the conference," commented Julianna Lisziewicz, CEO of the Company.
The European Conference for Clinical Nanomedicine is the annual scientific conference uniting clinicians and nanoscientists who have the common vision to apply nanoscience methods, tools and materials to the benefit of patients. It is a conference with European emphasis and international participation.
About Genetic Immunity
Genetic Immunity is a US/Hungarian development stage biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the Company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches.
Source: Genetic Immunity (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: